THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”) OR UNDER ANY STATE SECURITIES LAWS (“BLUE SKY LAWS”). NO TRANSFER,...Warrant Agreement • April 17th, 2012 • Fuse Science, Inc. • Investors, nec • Nevada
THIS CERTIFIES THAT, for good and valuable consideration, __________________ (“Holder”), or its registered assigns, is entitled to subscribe for and purchase from DOUBLE EAGLE HOLDINGS, LTD., a Nevada corporation (the “Company”), at any time after _____________, 2011, to and including ______________, 2016, _____________ (____) fully paid and non-assessable shares of the Common Stock of the Company (“Shares”) at the price of $0.12 per Share (the “Warrant Exercise Price”), subject to the anti-dilution provisions of this Warrant.
COMMERCIAL PROPERTY LEASECommercial Property Lease • April 17th, 2012 • Fuse Science, Inc. • Investors, nec • Florida
THIS LEASE is entered into on this 19 day January, 2012, between AARDVARK ONE LLC called Lessor, and FS CONSUMER PRODUCTS GROUP, INC. hereinafter referred to as Lessee herein.
SERIES B PLACEMENT AGENT WARRANTWarrant Agreement • April 17th, 2012 • Fuse Science, Inc. • Investors, nec • Nevada
THIS CERTIFIES THAT, for good and valuable consideration, ___________________ (“Holder”), or its registered assigns, is entitled to subscribe for and purchase from FUSE SCIENCE, INC., a Nevada corporation (the “Company”), at any time after February 9, 2012, to and including September 9, 2012, _______________________________ (________) fully paid and non-assessable shares of the common stock of the Company (“Shares”) at the price of $0.21 per Share (the “Warrant Exercise Price”), subject to adjustment pursuant to the anti-dilution provisions of this Warrant.
MANUFACTURING AGREEMENTManufacturing Agreement • April 17th, 2012 • Fuse Science, Inc. • Investors, nec • Florida
THIS MANUFACTURING AGREEMENT ("Agreement") is entered into this 2nd day of November, 2011 effective as of September 15, 2011 ("Effective Date") by and between FUSE SCIENCE INC., a Delaware corporation, having its principal place of business at 20900 NE 30th Ave., Eighth Floor, Miami, Florida 33180 ("Fuse Science"), Cure IP Holdings LLC ("Cure IP"), a Delaware limited liability company having its principle offices at 1620 Beacon Place Oxnard, CA 93033 and Cure Pharmaceutical Inc. ("Cure Pharma" or "Manufacturer") a California company license having its place of business at 1620 Beacon Place, Oxnard, CA 93033.
